Includes Depo-Provera CI and generic equivalents reported during intake.
Evidence-informed Depo-Provera review
Depo-Provera campaign information and records checklist
This campaign focuses on reported Depo-Provera or generic injectable medroxyprogesterone acetate use and a later intracranial meningioma diagnosis. Intake reviewers use product, timing, and medical records to understand each submission.
Depo-Provera campaign overview
Understand the campaign before starting your review
This campaign helps people document Depo-Provera or generic injectable medroxyprogesterone acetate use and a later intracranial meningioma diagnosis for a private intake review.
The FDA label describes a possible increased risk for meningioma growth, primarily with long-term use.
Federal product-liability cases are coordinated in the Northern District of Florida. Allegations remain contested.
This page provides intake information, not medical advice. Do not stop or change medication without speaking with a qualified healthcare professional.
Evidence-informed Depo-Provera review
Campaign guidance, records, and sources
Review the supporting information below before or after completing the private campaign form.
Official and authoritative background links used for intake education.
A practical checklist to help organize useful details before review.
Reviewed for intake accuracy by AMMS Compliance Team
Records and details that may help
- Prescription, injection, pharmacy, or provider records identifying the product and manufacturer when available
- Approximate first and last injection dates and total length of use
- Meningioma diagnosis records, imaging reports, pathology, and treatment timeline
- Names of prescribing providers, treatment facilities, and pharmacies
- Other hormone treatment history or medical details a reviewer may need to understand
Sources used for intake education
These official references are provided for background education only. They do not replace medical or legal advice.
- FDA 2025 Depo-Provera prescribing informationThe current FDA label describes a possible increased risk for growth of a meningioma, primarily with long-term use.
- FDA supplemental approval letterFDA approval record for adding meningioma information to warnings, counseling information, and patient materials.
- Federal court Depo-Provera MDL No. 3140Official Northern District of Florida page for the coordinated federal product-liability proceedings and current court documents.
- JPML transfer order for MDL No. 3140The Judicial Panel centralized the federal actions on February 7, 2025. The order summarizes the allegations and contested questions.
- European Medicines Agency safety reviewEMA safety review describing the meningioma signal for high-dose medroxyprogesterone, especially after prolonged use.
1. Submit the intake form
Share your contact details and answer the existing campaign-specific questions.
2. Organize supporting details
Gather the records, dates, communications, and other details listed for this campaign.
3. Intake follow-up
AMMS or an authorized intake partner may contact you for missing or clarifying details.
4. Legal review if appropriate
Qualified legal professionals decide whether a claim can move forward. AMMS does not provide legal advice or guarantee results.
Frequently asked questions
What is the current status of the Depo-Provera litigation?
Federal product-liability cases involving alleged meningioma injuries are coordinated in MDL No. 3140 in the Northern District of Florida for pretrial proceedings. Centralization does not decide whether the allegations are true or whether any individual claim qualifies.
What Depo-Provera records are helpful for intake?
Injection records, pharmacy records, prescribing-provider details, diagnosis records, imaging reports, and treatment timelines are useful for intake review.
Does the FDA label mention meningioma?
Yes. FDA-approved labeling updated in 2025 describes a possible increased risk for growth of a meningioma, primarily when the product is used for a long time. A label warning does not establish eligibility or causation for an individual claim.
Can AMMS tell me whether my medical condition was caused by Depo-Provera?
No. AMMS does not provide medical or legal causation opinions. Qualified medical and legal professionals evaluate those questions.
Related AMMS resources
AMMS Legal Intake Research TeamReviewed for intake accuracy by AMMS Compliance TeamLast reviewed: 2026-09-15
Important: AMMS provides intake and educational information. We are not providing medical or legal advice on this page, and submitting a form does not create an attorney-client relationship. Case value, eligibility, filing deadlines, and legal strategy must be reviewed by qualified professionals.